GLPG5101

About Galapagos

Galapagos is a commercial-stage biotech transitioning from a platform-centric discovery model to a lean, externally-focused business development engine. Its legacy is anchored by the successful JAK1 inhibitor filgotinib (Jyseleca), developed with Gilead, which provides European revenue and royalties. The company's current strategy, under new leadership, involves winding down internal cell therapy to redeploy capital towards acquiring late-stage clinical assets in high-value therapeutic areas like oncology and immunology, as exemplified by its new T cell engager collaboration with Gilead.

Therapeutic Areas